Download MendeleyDesign and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.
Gomez, L., Massari, M.E., Vickers, T., Freestone, G., Vernier, W., Ly, K., Xu, R., McCarrick, M., Marrone, T., Metz, M., Yan, Y.G., Yoder, Z.W., Lemus, R., Broadbent, N.J., Barido, R., Warren, N., Schmelzer, K., Neul, D., Lee, D., Andersen, C.B., Sebring, K., Aertgeerts, K., Zhou, X., Tabatabaei, A., Peters, M., Breitenbucher, J.G.(2017) J Med Chem 60: 2037-2051
- PubMed: 28165743
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01793
- Primary Citation of Related Structures:
5TZ3, 5TZA, 5TZC, 5TZH, 5TZW, 5TZX, 5TZZ, 5U00 - PubMed Abstract:
A series of potent and selective [1,2,4]triazolo[1,5-a]pyrimidine PDE2a inhibitors is reported. The design and improvement of the binding properties of this series was achieved using X-ray crystal structures in conjunction with careful analysis of electronic and structural requirements for the PDE2a enzyme. One of the lead compounds, compound 27 (DNS-8254), was identified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic properties. Interestingly, the increased potency of compound 27 was facilitated by the formation of a halogen bond with the oxygen of Tyr827 present in the PDE2a active site. In vivo, compound 27 demonstrated significant memory enhancing effects in a rat model of novel object recognition. Taken together, these data suggest that compound 27 may be a useful tool to explore the pharmacology of selective PDE2a inhibition.
Organizational Affiliation:
Dart Neuroscience LLC, 12278 Scripps Summit Drive, San Diego, California 92131, United States.
